Capricor says FDA inspection brought Form 483 with several observations
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today's best-performing stocks on TipRanks >>
Read More on CAPR:
Disclaimer & DisclosureReport an Issue
Largest borrow rate increases among liquid names
Capricor Therapeutics participates in a conference call with Maxim
Capricor Therapeutics Approves 2025 Equity Incentive Plan
MongoDB and Asana downgraded: Wall Street's top analyst calls
Capricor Therapeutics initiated with a Buy at Roth Capital
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
7 hours ago
- Wall Street Journal
Novo Nordisk's Weight Loss Lesson
Talk about dropping weight fast. See Novo Nordisk's 33.8% stock plunge this past week after it reduced its sales forecast. The Ozempic manufacturer has shed hundreds of billions of dollars in market value over the last year amid stepped-up competition. One lesson is that pharmaceutical cash cows rarely last long. Novo Nordisk slashed its profit forecast owing to slower sales growth for its Ozempic diabetes and Wegovy weight-loss treatments in the U.S. Its blockbuster GLP-1 drugs have been losing market share to Eli Lilly's Mounjaro and Zepbound. The latter has shown greater weight loss than Wegovy in some studies. Lilly is also building on its success with an experimental drug that can increase weight loss from fat and reduce loss of lean muscle mass. Its experimental once-a-day pill has shown comparable efficacy to Ozempic's weekly injectable. A pill would be less expensive to manufacture and more popular among patients. Both Lilly and Novo Nordisk previously struggled to scale up manufacturing to meet enormous demand for their weight-loss drugs. Under Food and Drug Administration rules, specialty pharmacies are allowed to produce knock-offs of drugs on its shortage list. Although the FDA has removed the drugs from its shortage list, some pharmacies continue to manufacturer them.
Yahoo
13 hours ago
- Yahoo
Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy
We recently compiled a list of Denali Therapeutics Inc. stands sixth on our list among the best future stocks. Denali Therapeutics Inc. (NASDAQ:DNLI) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, focused on developing therapies for neurodegenerative and lysosomal storage disorders. Its proprietary TransportVehicle (TV) technology enables the delivery of biologics across the blood-brain barrier, targeting neurological symptoms often left untreated by conventional therapies. In July 2025, the company achieved a major milestone as the FDA accepted and granted Priority Review for its Biologics License Application (BLA) for tividenofusp alfa, a novel enzyme replacement therapy for Hunter syndrome (MPS II). This designation highlights the urgent medical need and sets a PDUFA decision date of January 5, 2026, opening the door for potential approval and launch by early 2026. Tividenofusp alfa is a first-in-class brain-penetrant enzyme therapy designed to overcome a key limitation of current treatments, which do not reach the brain and fail to address neurological symptoms. In clinical trials, Denali Therapeutics Inc. (NASDAQ:DNLI)'s therapy demonstrated effective delivery of the missing enzyme to the central nervous system, showing promise for addressing both somatic and neurological aspects of Hunter syndrome. A scientist in a labcoat inspecting a microscope focusing on a microorganism related to the biopharmaceutical company's therapies. If approved, this therapy would not only offer new hope for patients with Hunter syndrome but also validate the corporation's TV platform, accelerating the development of additional treatments for other disorders like Sanfilippo syndrome (DNL126) and other central nervous system diseases. The milestone marks a transformative moment for Denali Therapeutics Inc. (NASDAQ:DNLI), potentially expanding its leadership in next-generation rare disease therapies. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
13 hours ago
- Yahoo
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal
We recently compiled a list of Arrowhead Pharmaceuticals, Inc. stands seventh on our list. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company specializing in RNA interference (RNAi) therapeutics for diseases with high unmet medical needs. Its proprietary TRiM platform enables precise silencing of disease-causing genes, positioning the company as a frontrunner in gene-targeted treatments and one of the best growth stocks in the biotech space. In July 2025, the company achieved a major milestone, a $100 million payment from Sarepta Therapeutics as part of a broader licensing and collaboration deal. The agreement includes clinical and preclinical RNAi candidates, offering the corporation up to $10 billion in potential milestone and royalty payments. This collaboration provides strong financial backing and external validation of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)'s RNAi technology. The business is making significant progress in the late-stage development of its cardiometabolic pipeline. In July 2025, the company initiated the Phase 3 YOSEMITE study for zodasiran in homozygous familial hypercholesterolemia. It also completed enrollment for several Phase 3 trials (SHASTA-3, SHASTA-4, and MUIR-3) evaluating plozasiran for severe hypertriglyceridemia and rare lipid disorders. Plozasiran's NDA has been accepted by the FDA, with a potential approval date of November 18, 2025. A biotechnologist in a lab setting, examining a sample of liquid for research and development. These developments underscore Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)'s momentum in bringing RNAi therapies to market. Positive Phase 3 results, including significant reductions in triglycerides and pancreatitis, highlight the strong efficacy of its treatments. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
